Browse Technologies

Displaying 11 - 20 of 24


Multisubstrate Inhibitors of Histone Acetylation Increase the Cytotoxicity of Chemotherapeutic Agents

Inhibitors of histone acetylation may constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Oncology

New Molecules Clear Chronic Infections by Disrupting Bacterial Energy Production Pathways

New compounds developed at Vanderbilt demonstrate a unique mechanism of broad spectrum activity to stymy antibacterial resistance. The compounds are particularly useful in chronic infections where long term antibiotic therapy fails, because it specifically kills "small colony variants" -- the bacteria that have developed resistance mechanisms. These compounds show promise in treating Methicillin-resistant S. aureus (MRSA), Bacillus anthracis (anthrax), and in overcoming difficult-to-treat infections in bone in cystic fibrosis patients. These compounds could be combined with new (and old) antimicrobial drugs to outwit resistant bacterial infections.


Licensing Contact

Karen Rufus

615.322.4295
Therapeutics

Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Cardiovascular

Small Molecule Mediated Transcriptional Induction of E-Cadherin and Inhibition of Epithelial-to-mesenchymal Transition


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Oncology

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Tom Utley

615.343.3852
Therapeutics

An Ergothioneine PET Radioligand for Imaging Oxidative Stress in Alzheimer's Disease

Vanderbilt researchers lead by Professor Wellington Pham, PhD, have developed a novel ergothioneine (ERGO) PET radioligand for imaging oxidative stress in Alzheimer's disease.


Licensing Contact

Masood Machingal

615.343.3548
Therapeutics
Neuroscience/Neurology

Cell-Permeable Socs Proteins That Inhibit Cytokine-Induced Signaling

Scientists at Vanderbilt have developed a unique polypeptide using cell-penetrating SOCS polypeptides or SOCS sequences designed to inhibits cytokine signaling and thus prevent or treat inflammation or an inflammatory related disease such as diabetes. This strategy has been validated in NOD mice models for either induced or naturally occurring diabetes and have been efficacious.


Licensing Contact

Clarissa Muere

615.343.2430
Therapeutics

Cooling-Responsive Gel for Local Drug Delivery Applications

Vanderbilt researchers have created a cooling-responsive gel implant that meets the need for non-invasive local drug delivery and is simple to activate, requiring only an ice pack for some applications, eliminating complex clinical equipment. This implant is ideal for alternative pain management or delivery of cancer therapeutics.


Licensing Contact

Philip Swaney

615.322.1067

Inventors

Leon Bellan
Therapeutics

Natural product for seizure relief and long term disease modification in Dravet Syndrome

Dravet syndrome is a lifelong form of epilepsy beginning in early childhood. Children with Dravet syndrome suffer aggressive seizures, impaired cognition, and an increased risk of premature death. Dravet syndrome does not respond to conventional anti-epileptic drugs, and current treatment regimens fail to fully elevate seizures. No disease modifying treatments exist. Researchers at Vanderbilt University have discovered a novel application of a known natural product in treating Dravet syndrome. This natural product could be beneficial to children suffering from Dravet syndrome in both reducing seizures and treating the underlying disease cause.


Licensing Contact

Tom Utley

615.343.3852

Inventors

Jingqiong Kang
Therapeutics
Neuroscience/Neurology